A -- Development and Commercialization of a Kit for the Diagnosis of Brain Tumors

The National Institute of Neurological Disease and Stroke (NINDS) of the National Institutes of Health (NIH) seeks a Cooperative Research and Development Agreement (CRADA) Collaborator to work with NINDS Intramural investigator in the development and commercialization of a kit for the histological diagnosis of primary brain tumor subtypes. NINDS has developed a method of identifying antigens expressed exclusively or greatly enriched in brain tumor cells. Potential Commercial Applications: - Clinical: histologic diagnosis of primary brain tumor subtypes - Research: isolation of tumor cells from surgical specimens for use in research studies Main Advantages of Technology/Invention: - Achieve simple, rapid and accurate diagnosis of primary brain tumor subtype to provide patients with appropriate prognostic information and therapeutic recommendations. - Enable researchers to efficiently separate tumor cells from the heterogenous population of mixed neoplastic and non-neoplastic cells present in surgical specimens Current State of Development - Preliminary identification of antigens expressed exclusively on astrocytomas or oligodendrogliomas Further R&D Required: - Determine antigenic epitopes of brain tumor specific proteins - Screen Collaborator's synthetic human antibody phage display library for antibodies to tumor specific antigens - Evaluate antibodies as diagnostic reagents Submission Dates: - Letter of interest should be received by Oct. 30, 2003. Proposals will be reviewed in order of receipt. Contact Information: - Martha T. Lubet, Ph.D. NINDS Technology Transfer by TTB/ NCI Phone: +1 (555) 000-0000 E-mail contact@example.gov